These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 34884316)

  • 21. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review.
    Cui S; Wang N; Liang Y; Meng Y; Shu X; Kong F
    Int Immunopharmacol; 2024 Nov; 141():112903. PubMed ID: 39146783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer.
    Bai R; Li L; Chen X; Chen N; Song W; Cui J
    Front Oncol; 2020; 10():575472. PubMed ID: 33163406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy.
    John AO; Ramnath N
    Oncologist; 2023 Sep; 28(9):752-764. PubMed ID: 37338126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy.
    Verma S; Breadner D; Mittal A; Palma DA; Nayak R; Raphael J; Vincent M
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer.
    Broderick SR
    Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials.
    de Scordilli M; Michelotti A; Bertoli E; De Carlo E; Del Conte A; Bearz A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review.
    Gatteschi L; Iannopollo M; Gonfiotti A
    Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer.
    Choong NW; Vokes EE
    Clin Lung Cancer; 2005 Dec; 7 Suppl 3():S98-104. PubMed ID: 16384544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer-Clinical Trials Experience.
    Chmielewska I; Stencel K; Kalinka E; Ramlau R; Krawczyk P
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions.
    Saw SP; Ang MK; Tan DS
    Curr Treat Options Oncol; 2022 Dec; 23(12):1721-1731. PubMed ID: 36451063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.
    Mielgo-Rubio X; Montemuiño S; Jiménez U; Luna J; Cardeña A; Mezquita L; Martín M; Couñago F
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic and targeted therapies for early-stage lung cancer.
    Byron E; Pinder-Schenck M
    Cancer Control; 2014 Jan; 21(1):21-31. PubMed ID: 24357738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC.
    Roller JF; Veeramachaneni NK; Zhang J
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35159008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.
    Isaacs J; Stinchcombe TE
    Drugs; 2022 Jun; 82(8):855-863. PubMed ID: 35596880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
    Melosky B; Juergens R; Hirsh V; McLeod D; Leighl N; Tsao MS; Card PB; Chu Q
    Oncologist; 2020 Jan; 25(1):64-77. PubMed ID: 31138727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
    Nagasaka M; Gadgeel SM
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):63-70. PubMed ID: 29168933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy.
    Shi Y; Ma X; He D; Dong B; Qiao T
    Front Immunol; 2023; 14():1213222. PubMed ID: 37600799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC.
    Bogatsa E; Lazaridis G; Stivanaki C; Timotheadou E
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy in patients with early stage resectable nonsmall cell lung cancer.
    Ghysen K; Vansteenkiste J
    Curr Opin Oncol; 2019 Jan; 31(1):13-17. PubMed ID: 30325753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review.
    Ortega-Franco A; Calvo V; Franco F; Provencio M; Califano R
    Transl Lung Cancer Res; 2020 Dec; 9(6):2656-2673. PubMed ID: 33489825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.